Trials show promise for intravitreal faricimab in retinal disease
(HealthDay)—Faricimab is noninferior to aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema, according to two studies published online Jan. 24 in The Lancet.
Feb 2, 2022
0
2